Drug Trial Radar · NCT07211776
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
108
Actual
Start
Dec 5, 2025
Primary completion
Mar 14, 2027
Study completion Jan 29, 2028
Sponsor
- Lead sponsor
- Zai Lab (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)
Conditions
- Thyroid Eye Disease (TED)
Interventions
ZL-1109 (VRDN-003)Drug
ZL-1109 subcutaneous injection
PlaceboDrug
Matching placebo subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proptosis Responder Rate in the study eyeTime frame: At Week 24
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Site01006
Beijing, China
Site01009
Beijing, China
Site01010
Beijing, China
Site01029
Bengbu, China
Site01020
Changsha, China
Site01022
Chengdu, China
Site01031
Chongqing, China
Site01011
Dalian, China
Site01008
Foshan, China
Site01004
Fuzhou, China
Site01007
Guangzhou, China
Site01027
Guiyang, China
Site01018
Hangzhou, China
Site01002
Hefei, China
Site01024
Jinan, China
Site01005
Luoyang, China
Site01017
Nanchang, China
Site01001
Shanghai, China
Site01012
Shenyang, China
Site01023
Taiyuan, China
Site01013
Tianjin, China
Site01016
Wuxi, China
Site01028
Xi'an, China
Site01026
Yangzhou, China
Site01019
Zhengzhou, China
Site01030
Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.